Likert与PI-RADS v2.1评分在前列腺多参数MRI中的异同:经组织学验证病例的图谱综述
英国NICE 2019指南推荐所有疑似前列腺癌患者在活检前接受多参数MRI,Likert评分系统基于多中心研究在英国国家医疗服务体系中被倡导使用。本文通过一系列经组织学证实的临床病例,综述了PI-RADS与Likert评估系统之间的相似性和具体差异。
要点
- NICE 2019指南推荐疑似前列腺癌患者活检前先行多参数MRI。
- Likert评分基于多中心研究在英国NHS内被倡导用于mpMRI报告。
- 本文通过组织学验证病例展示PI-RADS与Likert的相似性与具体差异。
核心结论
- 本文通过经组织学证实的临床病例,展示了PI-RADS与Likert评估系统之间存在的相似性和具体差异。
研究设计与样本
- 图谱综述,通过一系列经组织学证实的临床病例对PI-RADS与Likert评估系统进行比较。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The UK National Institute for Health and Care Excellence (NICE) 2019 "Prostate cancer: diagnosis and management" guidelines have recommended that all patients suspected of prostate cancer undergo multiparametric magnetic resonance imaging (mpMRI) prior to biopsy. The Likert scoring system is advocated for mpMRI reporting based on multicentre studies that have demonstrated its effectiveness within the National Health Service (NHS). In recent years, there has been considerable drive towards standardised prostate reporting, which led to the development of "Prostate Imaging-Reporting And Data System" (PI-RADS). The PI-RADS system has been adopted by the majority of European countries and within the US. This paper reviews these systems indicating the similarities and specific differences that exist between PI-RADS and Likert assessment through a series of histologically proven clinical cases.
引用
- Latifoltojar A, Appayya MB, Barrett T, et al. Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases. Clin Radiol. 2019. PMID: 31627804. doi:10.1016/j.crad.2019.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。